Vaccines for Pandemic Influenza

1
Vaccines for Pandemic Influenza

• Philip K. Russell, M.D.
• Avian Flu Conference, Baltimore, MD Jan 13,
  2006

2
Obstacles to the Use of Vaccines for Pandemic
Influenza

• Current manufacturing capacity
• 4 licensed U.S. manufacturers
• Egg based production
• Limited surge capacity
• Potential conflict with annual production of
  trivalent vaccine
• Long lead times
• 36 week manufacturing cycle

3
Obstacles to the Use of Vaccines for Pandemic
Influenza

• Time required to build and validate new
  facilities
• Time required to meet regulatory requirements for
  new vaccines
• Economics of a commodity vaccine
• Serotype variation
• Poor immunogenicity of avian serotypes
• Slow pace of RD for new vaccines

4
The Way Forward

• Establish diversified U.S. based manufacturing
  with surge capacity
• Cell culture methods
• Guaranteed annual purchase
• Increase annual vaccine utilization
• School Children
• Infants
• Health care workers

5
The Way Forward

• Improve surveillance world wide
• Accelerate RD efforts
• Adjuvants
• Cross protective vaccines
• Novel delivery systems
• Rapidly license adjuvanted vaccines
• Begin routine immunization with H5N1 strains (
  add to trivalent vaccine)